EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Quality by Design in Adaptive Oncology Clinical Trials: A Conceptual and Inspection-Focused Review

Meghashree N iD, Kushal C B, Vinayaka Mahadeo Shahavi, Shivaraj D R, Raviteja Venkata Bokka, Anusha N R

Therapeutic Innovation & Regulatory Science · 12.11.2026

DOI: 10.1007/s43441-026-01075-y ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 12.11.2026. Verfasst von Meghashree N und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Bapuji Pharmacy College, S.S. Layout, Shamanur Road, Davangere, Karnataka, 577004, India. meghashreen15@gmail.com. Die Arbeit nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Quality by Design (QbD) approaches have the potential to enhance the integrity of data, patient safety, and regulatory confidence in complex modern adaptive and platform oncology trials. Modern innovative trial designs like umbrella, basket and platform trials have the capacity to accelerate biomarker-based research but also carry inherent operational and statistical risks that call for sophisticated quality strategies. The core principle of clinical-trial QbD is prospective identification of factors critical to trial quality and proportionate management of risks during trial design and conduct, with emphasis on participant protection and the reliability and interpretability of trial results. Regulatory guidance such as International Council for Harmonisation (ICH) E6(R2) and E8(R1) encourages building quality into clinical trials and placing emphasis on endpoints important for benefit-risk assessment. Critical to this endeavor are effective critical-to-quality (CTQ)-quality tolerance limit (QTL)linkages, systematic risk assessment and appropriate governance of adaptive decision making to promote generation of credible evidence. The illustrative application illustrates how embedded quality controls and centralized monitoring during trial execution may enhance robustness and inspection readiness and provides examples of how predefined mitigation plans can support risk-proportionate trial conduct. In essence, QbD provides a framework for shifting the focus from data gathering toward decision assurance within oncology research.

Schlagwörter

Stichwörter der Autor:innen

Adaptive clinical trial designData qualityNeoplasmQuality controlsRisks management

Autor:innen und Institutionen

  • Department of Pharmacy Practice, Bapuji Pharmacy College, S.S. Layout, Shamanur Road, Davangere, Karnataka, 577004, India. meghashreen15@gmail.com.
  • , # 40, Srinandi, KHB Colony, Near Upper Bhadra Project Office, Huliyar road, Hosadurga, India. meghashreen15@gmail.com.
  • Department of Pharmacy Practice, Bapuji Pharmacy College, S.S. Layout, Shamanur Road, Davangere, Karnataka, 577004, India.
  • InoRx, Mumbai, Maharashtra, India.
  • Department of Pharmacy Practice, Akshaya Institute of Pharmacy, Tumkur, India.
  • Alkem Laboratories, Mumbai, India.

ORCID-Profile: Meghashree N

Zitieren

APA

N, M., C B, K., Shahavi, V. M., D R, S., Bokka, R. V., & Anusha N R (2026). Quality by Design in Adaptive Oncology Clinical Trials: A Conceptual and Inspection-Focused Review. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-026-01075-y

Vancouver

N M, C B K, Shahavi VM, D R S, Bokka RV, Anusha N R. Quality by Design in Adaptive Oncology Clinical Trials: A Conceptual and Inspection-Focused Review. Therapeutic Innovation & Regulatory Science. 2026. doi:10.1007/s43441-026-01075-y

BibTeX
@article{N2026,
  author = {N, Meghashree and C B, Kushal and Shahavi, Vinayaka Mahadeo and D R, Shivaraj and Bokka, Raviteja Venkata and Anusha N R},
  title = {Quality by Design in Adaptive Oncology Clinical Trials: A Conceptual and Inspection-Focused Review},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  doi = {10.1007/s43441-026-01075-y}
}
Kostenlos starten →